OMERS ADMINISTRATION Corp Purchases Shares of 7,400 Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

OMERS ADMINISTRATION Corp acquired a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 7,400 shares of the company’s stock, valued at approximately $410,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in TARS. Crowley Wealth Management Inc. acquired a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter worth about $25,000. R Squared Ltd bought a new stake in Tarsus Pharmaceuticals during the fourth quarter worth about $53,000. Quarry LP acquired a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter worth approximately $166,000. HighTower Advisors LLC acquired a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter worth approximately $207,000. Finally, Summit Investment Advisors Inc. raised its stake in shares of Tarsus Pharmaceuticals by 6.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company’s stock valued at $213,000 after acquiring an additional 244 shares during the last quarter. 90.01% of the stock is owned by institutional investors.

Insider Buying and Selling at Tarsus Pharmaceuticals

In related news, General Counsel Bryan Wahl sold 3,084 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $50.11, for a total transaction of $154,539.24. Following the transaction, the general counsel now owns 51,712 shares of the company’s stock, valued at $2,591,288.32. This trade represents a 5.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bobak R. Azamian sold 7,131 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total transaction of $330,093.99. Following the transaction, the chief executive officer now owns 70,720 shares of the company’s stock, valued at approximately $3,273,628.80. This represents a 9.16% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 32,542 shares of company stock valued at $1,581,173. 8.25% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research firms recently commented on TARS. HC Wainwright restated a “buy” rating and set a $73.00 price target on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. Guggenheim increased their target price on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the stock a “buy” rating in a report on Friday, May 2nd. Barclays lowered their target price on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th. The Goldman Sachs Group upped their price target on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a “neutral” rating in a research report on Monday, May 5th. Finally, Jefferies Financial Group raised their price objective on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $66.33.

Tarsus Pharmaceuticals Trading Up 3.0%

Shares of TARS opened at $45.01 on Tuesday. The stock’s fifty day simple moving average is $48.01 and its 200-day simple moving average is $49.22. The firm has a market capitalization of $1.89 billion, a PE ratio of -11.81 and a beta of 0.94. Tarsus Pharmaceuticals, Inc. has a 12-month low of $20.08 and a 12-month high of $57.28. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its earnings results on Thursday, May 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The company had revenue of $78.34 million for the quarter, compared to analyst estimates of $72.50 million. As a group, research analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.